EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Annexin A2 antibodies in post-treatment Lyme disease

John B Miller iD, Alison W Rebman, Marcia Daniela Villegas de Flores, Hong Wang, Erika Darrah, John N Aucott

Therapeutic Advances in Infectious Disease · 2024-01 · 11

DOI: 10.1177/20499361241242971 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Therapeutic Advances in Infectious Disease, online erschienen am 30.03.2024. Verfasst von John B Miller und 5 weiteren Autor:innen. Beteiligte Einrichtung: Division of Rheumatology, Johns Hopkins University School of Medicine, 5200 Eastern Avenue, Mason F Lord Building Center Tower, Suite 4100, Baltimore…. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Jerome L. Greene Foundation, National Institute of Arthritis and Musculoskeletal and Skin Diseases, Rheumatology Research Foundation Career Development Funding Award: K Bridge.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Anti-annexin A2 (AA2) antibodies have been described in Lyme arthritis and erythema migrans, although they have not been described in post-treatment Lyme disease (PTLD).

Objectives

Determine whether anti-AA2 antibodies are present among patients with PTLD and determine the clinical relevance of these antibodies. Design and methods: Anti-AA2 levels were tested serially in a longitudinal cohort of 44 patients with acute Lyme disease, 22 with a return to health (EM RTH), and 22 with PTLD. Anti-AA2 antibodies were also assessed in a cross-sectional group of 281 patients with PTLD.

Results

Anti-AA2 antibodies were highest after antimicrobial therapy in both the EM RTH and PTLD cohorts. By 6 months, there was no difference between EM RTH and healthy controls. Anti-AA2 antibodies were higher in the cross-sectional PTLD group (79.69 versus 48.22 units, p < 0.0001), though with no difference in total symptom burden.

Conclusion

Anti-AA2 persists in PTLD, though did not identify a clinical phenotype.

Schlagwörter

Stichwörter der Autor:innen

Lyme diseaseanti-Annexin A2autoantibodies

Autor:innen und Institutionen

  • Division of Rheumatology, Johns Hopkins University School of Medicine, 5200 Eastern Avenue, Mason F Lord Building Center Tower, Suite 4100, Baltimore, MD 21224, USA.
  • Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.

ORCID-Profile: John B Miller

Förderung

  • Jerome L. Greene Foundation
  • National Institute of Arthritis and Musculoskeletal and Skin Diseases
  • Rheumatology Research Foundation Career Development Funding Award: K Bridge

Zitieren

APA

Miller, J. B., Rebman, A. W., de Flores, M. D. V., Wang, H., Darrah, E., & Aucott, J. N. (2024). Annexin A2 antibodies in post-treatment Lyme disease. Therapeutic Advances in Infectious Disease, 11. https://doi.org/10.1177/20499361241242971

Vancouver

Miller JB, Rebman AW, de Flores MDV, Wang H, Darrah E, Aucott JN. Annexin A2 antibodies in post-treatment Lyme disease. Therapeutic Advances in Infectious Disease. 2024;11. doi:10.1177/20499361241242971

BibTeX
@article{Miller2024,
  author = {Miller, John B and Rebman, Alison W and de Flores, Marcia Daniela Villegas and Wang, Hong and Darrah, Erika and Aucott, John N},
  title = {Annexin A2 antibodies in post-treatment Lyme disease},
  journal = {Therapeutic Advances in Infectious Disease},
  year = {2024},
  volume = {11},
  doi = {10.1177/20499361241242971}
}
Kostenlos starten →